A retrospective study to compare short and long-term effectiveness of vedolizumab and ustekinumab in Crohn's disease patients with prior anti-TNF exposure
Latest Information Update: 06 Jul 2021
At a glance
- Drugs Ustekinumab (Primary) ; Ustekinumab (Primary) ; Vedolizumab (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- 23 May 2021 Results presented at the Digestive Disease Week 2021
- 06 May 2021 New trial record
- 28 Apr 2021 Primary endpoint (Corticosteroid-free clinical remission at Week 54 defined as CDAI < 150 without resort to surgery) has been met , according to Results published in the Alimentary Pharmacology and Therapeutics